PMID- 16690517
OWN - NLM
STAT- MEDLINE
DCOM- 20070926
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 47
IP  - 4
DP  - 2006 Apr
TI  - The efficacy of unrelated cord blood transplantation for adult myelodysplastic 
      syndrome.
PG  - 599-602
AB  - Although allogeneic stem cell transplantation from a human leukocyte antigen 
      (HLA)-identical related donor offers a potential cure for patients with 
      myelodysplastic syndrome (MDS), a suitably matched related donor is unavailable 
      for approximately two thirds of patients. Recently, umbilical cord blood from 
      unrelated donors have been used as an alternative stem cell source for adult 
      patients with MDS. Here, we updated the results of unrelated cord blood 
      transplantation (CBT) after myeloablative conditioning for 22 adult patients with 
      MDS. Diagnosis at transplantation included refractory anemia (RA) (n = 3), 
      refractory anemia with excess blasts (RAEB) (n = 2), RAEB-t (n = 2), and 
      MDS-related secondary acute myeloid leukemia (AML) (n = 15). All patients were 
      treated with total body irradiation (12 Gy), cytosine arabinoside (Ara-C) and 
      cyclophosphamide followed by unrelated HLA-mismatched CBT. The median age was 40 
      years (range, 19 - 51 years), the median weight was 54.5 kg (range, 43 - 75 kg), 
      and the median number of cryopreserved nucleated cells was 2.43 x 10(7)/kg 
      (range, 1.82 - 4.10 x 10(7)/kg). Twenty one patients had myeloid reconstitution 
      and the median time to more than 0.5 x 10(9)/l absolute neutrophil count was 22.5 
      days. A self-sustained platelet count more than 50 x 10(9)/l was achieved in 19 
      patients at a median time of 49 days. Acute GVHD above grade II occurred in seven 
      of 21 evaluable patients and chronic GVHD in 16 of 19 evaluable patients. Among 
      16 chronic GVHD patients, in eight patients the disease was extensive. Seventeen 
      patients are alive and free of disease at between 371 and 2562 days after 
      transplantation. With a median follow-up of 1505 days, the probability of 
      disease-free survival at 4 years was 76.0%. These results suggest that adult MDS 
      patients without suitable related or unrelated bone marrow donors should be 
      considered as candidates for CBT.
FAU - Ooi, Jun
AU  - Ooi J
AD  - Department of Hematology and Oncology, Institute of Medical Science, University 
      of Tokyo, Tokyo, Japan. jun-ooi@ims.u-tokyo.ac.jp
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
CIN - Leuk Lymphoma. 2006 Apr;47(4):569-70. PMID: 16690515
MH  - Adult
MH  - Anemia, Refractory/therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Fetal Blood/*cytology/*metabolism
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/metabolism/*therapy
MH  - Probability
MH  - Stem Cell Transplantation/*methods
MH  - Tissue Donors
MH  - Transplantation Conditioning
MH  - Transplantation, Homologous
EDAT- 2006/05/13 09:00
MHDA- 2007/09/27 09:00
CRDT- 2006/05/13 09:00
PHST- 2006/05/13 09:00 [pubmed]
PHST- 2007/09/27 09:00 [medline]
PHST- 2006/05/13 09:00 [entrez]
AID - J173747011L87275 [pii]
AID - 10.1080/10428190500421013 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2006 Apr;47(4):599-602. doi: 10.1080/10428190500421013.